NCPA and the Alliance for Pharmacy Compounding (APC) submitted joint comments to the Food and Drug Administration's request for information on testosterone replacement therapy (TRT) in men with hypogonadism. Among other things, NCPA and APC spoke to both the clinical benefit and the positive safety profile of TRT.
Read the comments here.
NCPA
